Managing Malassezia Species and Related Infections: New Insights into Recent Natural and Synthetic Antifungal Compounds and Their Mechanism of Action
Iacovozzi D, Carradori S, Osmanović A, Supuran CT, Capasso C, Angeli A
Summary
This comprehensive review examines emerging therapeutic strategies against Malassezia yeasts, which cause seborrheic dermatitis, pityriasis versicolor, and systemic infections in immunocompromised patients. A key focus is the growing interest in antimicrobial peptides — both natural and synthetic — as targeted topical antifungal agents, alongside novel approaches including carbonic anhydrase inhibition, silver nanoparticles, and probiotics/postbiotics.
Clinical Significance
With increasing azole resistance in Malassezia species, antimicrobial peptides represent a promising new class of topical antifungal agents. This review highlights the pipeline of AMP-based formulations that could address the growing treatment gap in dermatologic mycology.
Key Findings:
- Malassezia carbonic anhydrases identified as selective antifungal targets
- Antimicrobial peptides offer targeted topical formulation potential
- Probiotics/postbiotics may restore skin microbiome balance
- Multi-modal approaches (peptides + nanoparticles + enzyme inhibitors) show synergistic potential
- Addresses growing azole resistance in Malassezia
Clinical Takeaway: Antimicrobial peptides may soon provide clinicians with targeted, resistance-resistant topical treatments for Malassezia-driven skin conditions, an area with limited therapeutic options.
Links:
Penelitian Terkait
Peptide Angio-3 Attenuates Pulmonary Fibrosis Via Modulation of Coagulation Factor Xa-PAR-1 Signaling Axis
Angio-3, a 10-residue peptide derived from human plasminogen kringle 3, demonstrated significant ant…
Antimicrobial Peptides Show Promise as Cancer Therapeutics: A 2026 Systematic Review
A new review in Frontiers in Medicine evaluates antimicrobial peptides (AMPs) as anticancer agents, …
Pemvidutide Achieves MASH Resolution in Phase 2b IMPACT Trial
The Lancet published Phase 2b results for pemvidutide, a dual GLP-1/glucagon agonist, showing signif…
Retatrutide Achieves 28.7% Weight Loss in TRIUMPH-4 Phase 3 Trial
Eli Lilly's triple GIP/GLP-1/glucagon agonist retatrutide achieved an average 28.7% body weight redu…